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 8 
Summary 9 
Outbreaks or clusters of community-acquired meticillin-resistant Staphylococcus aureus 10 
(CA-MRSA) within families have been reported. We describe a family cluster of CA-MRSA 11 
skin and soft-tissue infection where CA-MRSA was suspected because of recurrent infections 12 
which failed to respond to flucloxacillin. While the prevalence of CA-MRSA is low 13 
worldwide, CA-MRSA should be considered in certain circumstances depending on clinical 14 
presentation and risk assessment. Surveillance cultures of family contacts of patients with 15 
MRSA should be considered to help establish the prevalence of CA-MRSA and to inform the 16 
optimal choice of empiric antibiotic treatment.  17 
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Introduction  1 
Meticillin-resistant Staphylococcus aureus (MRSA) has been traditionally associated with 2 
healthcare-associated (HA) infections.  Established risk factors for HA-MRSA infections 3 
include recent hospitalization or surgery, dialysis, residence in a long-term care facility, and 4 
indwelling catheters or percutaneous medical devices (Naimi et al., 2003). However, new 5 
strains of MRSA have emerged in the community which cause infection in patients who have 6 
no previous history of direct or indirect healthcare contact. These infections are referred to as 7 
community-acquired or community-associated MRSA (CA-MRSA). The isolates causing 8 
these infections are reported to be genetically and phenotypically distinct from HA-MRSA as 9 
the strains are typically more susceptible to a wider range of anti-staphylococcal antibiotics 10 
and often produce the Panton-Valentine leukocidin (PVL) toxin (Vandenesch et al., 2003).  11 
 12 
CA-MRSA infections have been reported in North America, Europe, Australia and New 13 
Zealand (Vandenesch et al., 2003; Dufour et al., 2002; Okuma et al., 2002; Adhikari et al., 14 
2002). Most cases have been associated with skin and soft tissue infection (SSTI) or 15 
necrotising pneumonia. Here, we described intra-familial spread of CA-MRSA associated 16 
with SSTI and discuss its implications. 17 
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Case Report 1 
A previously healthy 42-year-old mother presented to her general practitioner with an abscess 2 
on her leg. She gave a history of two previous abscesses on her legs and buttock in the last 3 
seven months. She received several courses of oral flucloxacillin with some clinical 4 
resolution of the abscess on each occasion and no specimen was sent for culture. A few days 5 
prior to the most recent presentation, her husband presented with an abscess on his face and 6 
14 days later, their 5-year-old son presented with a boil on his nose. Neither her husband nor 7 
her son presented with previous history of soft tissue infection. 8 
 9 
Swabs were taken from the abscesses and the boil. MRSA were isolated from the swabs from 10 
these three family members. Both parents were treated with oral doxycycline with no further 11 
recurrence of their abscesses; the son did not require systemic antibiotics. Two other sons 12 
were MRSA-negative on screening. On further enquiry, the family reported no involvement 13 
with contact sports, animal contacts or contact with known MRSA carriers. Both parents are 14 
from the European Union, with the mother having been born and educated in Ireland.  There 15 
was no migration background and no travel history in the last two years such as to Australia 16 
and New Zealand.  Consequently, the original source of these isolates remains unknown. 17 
 18 
Isolate identification and antimicrobial susceptibility testing was performed initially using an 19 
automated system (Phoenix™ 100: BD Biosciences, Sparks, MD, USA). Susceptibility was 20 
confirmed by disk diffusion according to Clinical and Laboratory Standards Institute 21 
methodology (CLSI, 2007). All three isolates were resistant to β-lactam antibiotics and 22 
susceptible to aminoglycosides, chloramphenicol, ciprofloxacin, erythromycin, fusidic acid, 23 
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lincomycin, linezolid, mupirocin, rifampicin, tetracycline, trimethoprim and vancomycin. The 1 
isolates were also susceptible to daptomycin with E-test minimum inhibitory concentration 2 
(MIC) of <1 mg/L and to tigecycline with MIC of 0.5 ml/L; the breakpoint for daptomycin 3 
according to CLSI 2009 guidelines and for tigecycline by Kronval et al 2006. Further 4 
characterisation showed the isolates to be urease-positive and to carry the genes encoding the 5 
PVL toxin. DNA macro-restriction analysis yielded a pattern designated 02033 which is 6 
indistinguishable from the pattern exhibited by CA-MRSA isolates reported from Ireland that 7 
belonged to multilocus sequence type (MLST) ST30 and carried the staphylococcal cassette 8 
chromosome mec (SCCmec) type IV element (Rossney et al., 2007). Staphylococcal protein 9 
A (spa) gene sequence typing showed that the isolates belonged to spa type t019. This spa 10 
type is also associated with ST30 according to data held in the Ridom Spa Server database 11 
(http://spaserver.ridom.de ). 12 
 13 
Discussion 14 
The overall prevalence of CA-MRSA is low worldwide but there is evidence that this is 15 
increasing mainly in the USA, Canada, Australia, Greece and Denmark (Salgado et al., 2003; 16 
Vourli et al., 2009; Sdougkos et al., 2008; Larsen et al., 2009). CA-MRSA is also an 17 
emerging challenge in Ireland (Rossney et al., 2007). Clusters and outbreaks of CA-MRSA 18 
have been described in specific groups of individuals such as Native Americans in the USA, 19 
men who have sex with men, prison inmates, military recruits, competitive sports participants 20 
and children attending childcare centres (Weber, 2005). Several risk factors for CA-MRSA 21 
acquisition have been identified. These include crowded living conditions, closed 22 
communities with people in close contact, participation in contact sports, poor hygiene, 23 
compromised skin integrity, exposure to contaminated items, prior MRSA infection and 24 
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previous antibiotic exposure (HPA, 2008; Popovich & Hota, 2008). None of these risk factors 1 
applied to the family cluster reported here.  2 
 3 
The spectrum of clinical infections caused by CA-MRSA differs from that caused by HA-4 
MRSA. HA-MRSA isolates commonly cause bloodstream, urinary tract and respiratory tract 5 
infections. CA-MRSA infections are more likely to involve SSTI (Naimi et al., 2003). 6 
However, severe necrotising pneumonia due to CA-MRSA has occasionally been described 7 
(Jones et al., 2006; Gorak et al., 1999). The case described in the present report is intra-8 
familial spread of CA-MRSA infection in a family cluster characterised by SSTI with no 9 
history of risk factors for HA-MRSA.  10 
 11 
The optimal management of S. aureus SSTI with abscesses formation especially abscesses 12 
less than 5 cm in diameter is incision and drainage without adjunctive antibiotics.  However, 13 
systemic antibiotics should be considered in immunocompromised patients, infants, patients 14 
with multiple areas of skin and soft tissue infections (especially abscesses >5cm), infections 15 
that do not respond to incision and drainage or if there is clinical deterioration (HPA, 2008; 16 
Popovich & Hota, 2008). Compared with MRSA, meticillin-susceptible S. aureus (MSSA) is 17 
still the more prevalent cause of SSTI in the community and a recent study has shown that 18 
62% of PVL-positive S. aureus isolates (444/720) were MSSA (HPA, 2008). Therefore β-19 
lactam antibiotics are still the choice for empiric therapy for the young and for clinically 20 
stable patients in the community. However, CA-MRSA should be suspected if there are 21 
recurrent skin infections or abscesses that are unresponsive to β-lactam therapy and/or if there 22 
is a history of spread within the family. Specimens for culture should be taken in the 23 
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community by general practitioners if the infection persists or progresses while the patient is 1 
receiving appropriate antibiotics directed towards MSSA. 2 
 3 
Meticillin resistance in S. aureus is mediated by the mecA gene which encodes an altered 4 
penicillin binding protein (PBP) PBP2a with low affinity for β-lactam antibiotics. The mecA 5 
gene together with its regulators, mecI and mecRI is carried on the SCCmec mobile element. 6 
There are at least seven main types of SCCmec (types I−VII) and numerous subtypes 7 
SCCmec (Deurenberg &, Stobberingh 2009). CA-MRSA is associated with the SCCmec 8 
elements SCCmec types IV and V (Rossney et al., 2007; Vourli et al., 2009; Sdougkos et al., 9 
2008; Larsen et al., 2009; Otter et al., 2009). CA-MRSA frequently carries the pvl genes 10 
which code for a cytotoxin that causes tissue necrosis and leucocyte destruction by forming 11 
pores in cellular membrane. PVL is an established virulence factor in the pathogenesis of 12 
infection associated with CA-MRSA but other factors such as the arginine catabolism mobile 13 
element (ACME), and/or other cytolytic peptides may also be important (Diep et al. 2008; 14 
Tseng et al. 2009; HPA, 2008; Labandeira-Rey et al., 2007; Gillet et al., 2002).  15 
 16 
It is reported that CA-MRSA strains can be distinguished from HA-MRSA strains because 17 
they are generally susceptible to antimicrobials other than β-lactams and carry the pvl genes 18 
(Naimi et al., 2003). It is also reported that CA-MRSA from different geographic areas 19 
exhibit different MLSTs with ST80 being associated with Europe, ST93 with Australia, ST30 20 
with Oceania, and ST1, ST59 and ST8 with the USA (Vandenesch et al., 2003). A recent 21 
study showed that PVL-positive CA-MRSA from Ireland exhibited a range of six MLST 22 
types with ST30 and ST8 occurring most frequently and that only 6.7% of CA-MRSA carried 23 
the pvl genes (Rossney et al., 2007). In that study, 36% of pvl-positive isolates came from 24 
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patients of non-Irish ethnic origin. An earlier study from Ireland had also shown that the 1 
predominant strain among HA-MRSA exhibited a non-multi-antibiotic-resistant phenotype 2 
and carried SCCmec IV (Rossney et al., 2006). Hence neither carriage of pvl genes or 3 
SCCmec IV nor a susceptible antibiogram can be used as sole markers for CA-MRSA in 4 
Ireland (Rossney et al., 2007) and a time-based definition such as detection of MRSA within 5 
24 or 48 hours of hospital admission or detection in a patient without healthcare-associated 6 
risk factors must be used. 7 
 8 
Screening and decolonisation therapy are important components in the prevention and control 9 
of HA-MRSA (Kluytmans et al., 1997; Davis et al., 2004; Cosgrove et al., 2003). Studies 10 
have shown that the identification of CA-MRSA colonisation may require screening of sites 11 
other than the nares but the efficacy of CA-MRSA decolonisation is unclear (Popovich & 12 
Hota, 2008; Zafar et al., 2007). Guidelines for the management of PVL-associated S. aureus 13 
in England recommend topical decolonisation without prior screening of the primary case 14 
(HPA, 2008). Decolonisation therapy is also part of the MRSA control guidelines in 15 
Denmark and Greece (Vourli et al., 2009; Larsen et al., 2009). Screening and decolonisation 16 
of contacts should be considered where close contacts are infected or where they pose a 17 
special risk to others (e.g. healthcare workers). However, the key principles of prevention and 18 
control of CA-MRSA are early diagnosis and treatment, ensuring lesions are covered with 19 
clean dressings, good personal hygiene, not sharing personal items, laundry using a hot-wash 20 
cycle, regular household cleaning and the avoidance of communal and recreational settings 21 
by infected patients. Patients in occupations at high risk for transmission of CA-MRSA such 22 
as healthcare workers should be excluded from work until lesions have healed (HPA, 2008). 23 
 24 
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Surveillance for CA-MRSA is important as information is needed on the baseline frequency 1 
of CA-MRSA colonisation in Ireland compared with other countries. Increasing CA-MRSA 2 
prevalence will affect the choice of appropriate empiric antibiotics to optimise patient care 3 
and may pose risk of hospital spread if infected patients require admission to hospital. 4 
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